Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bromolysergide hydrobromide
- Development stage
- Unknown
- Lead developer
- BetterLife Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
2-Bromolysergic acid diethylamide hydrobromide (also known as BOL-148 or BETR-001) is a non-hallucinogenic derivative of lysergic acid diethylamide (LSD). It acts as a partial agonist at the serotonin 5-HT2A receptor, but unlike LSD, it does not induce psychedelic effects, likely due to differences in signaling bias or receptor kinetics. The compound is primarily being investigated for the prophylactic treatment of cluster headaches, a condition characterized by intense, recurring pain. It has also been explored for other cephalic pain disorders and potentially neuropsychiatric conditions such as depression and PTSD. BetterLife Pharma is the primary developer of this compound under the codes BETR-001 and TD-0148A.
- Other names
- 2-bromolysergic acid diethylamide hydrobromide2-Bromo-LSDbromolysergide2-bromolysergic acid diethylamide
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on bromolysergide hydrobromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bromolysergide hydrobromide.